Integrated Drug Discovery
Offering End-to-End Solutions
IND-Enabling Projects
Axcelead acquired multiple projects from Takeda through its spin-out in 2017 in multiple therapeutic areas including Oncology, Inflammation and Immunology, Cardiovascular/Metabolic Disease and Neuroscience. These exciting projects are available for co-creation of drug candidates with our customers. The IND-Enabling Projects provide an opportunity for newly generated IP, which is owned by our customers. To help you advance an IND-Enabling Projects, Axcelead drug discovery services are capable of advancing projects to IND filing and beyond.
Currently, we have 180+ small molecule and peptide projects against the select below high-value therapeutic targets:
- ERBB4 inhibitor
- IAP antagonist
- MAPK14 inhibitor
- HCN4 inhibitor
If you are interested in learning more, please reach out directly to our business development department.
Click here for service details.